OFFICE NO 5 & 6, 3RD FLOOR,
EARTH ALPHA COMPLEX
VASNA BHAYLI RD, VADODARA
GUJARAT, INDIA
What Is Pharmaceutical In-Licensing?
Pharmaceutical in-licensing occurs when a company obtains permission from another party to use specified rights relating to a pharmaceutical product or technology.
Depending on the agreement, these rights may cover development, manufacturing, use of technical information or commercialisation in particular markets.
The company receiving the rights is known as the licensee. In-licensing can help it expand its portfolio or access capabilities that it does not own.
However, the company receives only the rights specified in the agreement. Permission to market a product does not automatically include permission to manufacture it, modify its formulation or grant rights to another partner.
What Is Pharmaceutical Out-Licensing?
Pharmaceutical out-licensing occurs when a rights holder grants another company permission to use specified product or technology rights.
The party granting the rights is known as the licensor. It may use out-licensing to work with a partner that has suitable development capabilities, manufacturing resources or access to a particular market.
A licence generally grants permission to use intellectual property rather than transferring ownership of it. The permitted activities, territory and duration depend on the agreement.
For example, a company may grant a partner rights to commercialise a product in selected countries while retaining rights in other markets.
How In-Licensing and Out-Licensing Work Together
In-licensing and out-licensing usually describe the same transaction from different perspectives.
Consider a hypothetical company that holds rights to a pharmaceutical formulation. It grants another company permission to develop and commercialise that formulation in an agreed territory.
The rights holder is out-licensing the formulation. The partner receiving the rights is in-licensing it.
Their agreement should establish what each party can do, which rights remain with the owner and how responsibilities and payments will be managed.
Why Do Pharmaceutical Companies Use Licensing Partnerships?
Licensing can help pharmaceutical companies combine complementary resources.
One business may have a product or technology, while another has the expertise and infrastructure needed to develop it further or introduce it to a specific market.
Potential reasons for entering a licensing partnership include:
These benefits depend on the suitability of the product, the capabilities of both parties and the terms of the arrangement.
What Global Partners Should Check
Before entering a pharmaceutical licensing arrangement, partners should evaluate the product, the rights available and the obligations they would accept.
1. Ownership and Authority to Grant Rights
The prospective licensee should confirm that the licensor owns or controls the rights it proposes to grant.
Relevant checks may include patent ownership, trademark rights, rights to technical information and restrictions imposed by earlier agreements.
If a company is offering a sublicence, partners should verify that its original agreement permits it to do so.
Existing licences, disputes or other restrictions may affect the proposed partnership.
2. Product and Development Status
Partners should establish whether the opportunity concerns an early-stage development project, a product awaiting approval or an already authorised medicine.
The available evidence and remaining work can differ substantially between these situations.
Review the relevant technical, quality, nonclinical and clinical information where applicable. Identify missing information and determine who will be responsible for generating it.
An existing approval in one country should not be assumed sufficient for another market.
3. Territory and Scope of Rights
The agreement should identify the countries, products and activities covered.
Partners should clarify whether the licence includes development, manufacturing, importing, marketing, distribution or use of a particular trademark.
They should also establish whether the arrangement is exclusive or non-exclusive and whether sublicensing is permitted. Licensing terms can restrict rights by territory, field of use and activity.
Clear boundaries help prevent misunderstandings about where and how a partner can operate.
4. Regulatory Responsibilities
A commercial licensing agreement does not itself provide regulatory approval to market a medicine.
Partners should identify the approvals required in the destination market and agree who will prepare submissions, respond to regulatory questions and maintain the relevant authorisations.
Where an existing marketing authorisation must change holder, a separate regulatory procedure may apply. For example, the European Medicines Agency provides a formal transfer process for centrally authorised medicines.
The commercial agreement and regulatory plan should therefore be coordinated before launch.
5. Manufacturing and Quality Arrangements
Partners should understand where the product will be manufactured and whether the proposed facilities are suitable for the intended markets.
They should agree responsibilities for specifications, testing, batch release, stability monitoring, complaints, deviations and recalls, as applicable.
If manufacturing technology will be transferred, the parties should define the required documentation, training, validation activities and acceptance criteria.
Access to a formulation alone may not provide everything necessary to manufacture the product consistently.
6. Commercial Terms
Licensing arrangements may include upfront payments, milestone payments, royalties or a combination of these.
Partners should clearly define payment triggers, calculation methods, reporting requirements and any relevant audit rights.
Where royalties depend on sales, the agreement should explain how the sales base and permitted deductions are calculated.
Commercial evaluation should also account for development costs, registration work, manufacturing expenses and launch requirements.
7. Supply Reliability
If the arrangement includes product supply, partners should agree the practical terms needed to support it.
These may include forecasts, minimum order quantities, lead times, shelf-life expectations, storage conditions and delivery arrangements.
The parties should also address how shortages, manufacturing changes and discontinuation will be managed.
Licensing rights and supply commitments should be reviewed together so that commercial plans reflect actual product availability.
8. Safety Monitoring and Ongoing Support
Partners should clearly allocate responsibilities for exchanging safety information, handling product complaints and supporting applicable reporting obligations.
They should establish contact points, information-sharing procedures and escalation arrangements.
Ongoing cooperation may also be needed for regulatory updates, product changes and quality investigations throughout the partnership.
How Licensing Differs from Pharmaceutical Distribution
A distribution agreement generally focuses on purchasing, supplying and selling products through agreed channels.
A licensing agreement focuses on permission to use defined rights, such as intellectual property or technology.
Some partnerships include both. A distributor may receive permission to use a trademark, while a licensee may also enter a separate product supply agreement.
Partners should examine the actual rights and obligations rather than relying only on the agreement’s title.
Pharmaceutical Licensing Partnerships Involving India
International companies considering licensing opportunities involving Indian pharmaceutical businesses should evaluate each opportunity individually.
The review should establish which entity holds the relevant rights, which manufacturer will supply the product and what technical and regulatory information is available.
Partners should also determine whether the proposed arrangement involves finished-product supply, dossier access, trademark licensing, technology transfer or a combination of these activities.
A pharmaceutical exporter’s ability to supply medicines does not automatically establish that it owns the rights required for a licensing transaction.
Why Due Diligence Matters
Due diligence helps partners assess whether the opportunity is technically, commercially and operationally suitable before committing to it.
This process should examine both the offered rights and the prospective partner’s ability to fulfil its obligations. WIPO’s licensing guidance identifies due diligence as an important step in evaluating licensing transactions.
Potential issues may include incomplete documentation, restricted rights, unrealistic timelines or insufficient resources for development and launch.
Identifying these issues early allows partners to resolve gaps or reconsider the proposed arrangement.
Building a Reliable Global Licensing Partnership
A successful pharmaceutical licensing relationship requires clear communication and realistic expectations.
Before starting work, partners should agree responsibilities, deliverables, timelines and procedures for managing changes. They should also address confidentiality, ownership of improvements, termination and the handling of remaining products and information when the relationship ends.
Pharmaceutical in-licensing and out-licensing can support portfolio development and international expansion when the rights, evidence and operational capabilities align.
For global partners, careful evaluation and clearly defined agreements provide a stronger foundation for managing the product throughout its commercial lifecycle.
Share This News